This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Merck + Co., Inc.. Active years: 2009.
Company Filing History:
Years Active: 2009
Title: Kenneth Alan Koeplinger: Innovator in RNA Viral Infection Treatment
Introduction
Kenneth Alan Koeplinger is a notable inventor based in Lansdale, PA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the treatment of RNA-dependent RNA viral infections. His innovative work has led to the development of a unique patent that addresses critical health challenges.
Latest Patents
Koeplinger holds a patent for "Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection." This invention provides ribonucleoside 2',3'-cyclic acetals that serve as precursors or prodrugs of inhibitors targeting RNA-dependent RNA viral polymerase. These compounds are particularly effective against hepatitis C virus (HCV) NS5B polymerase and are useful in treating hepatitis C infections. The patent also includes pharmaceutical compositions containing these ribonucleoside cyclic acetals, either alone or in combination with other antiviral agents.
Career Highlights
Kenneth Alan Koeplinger is associated with Merck & Company, Inc., a leading global healthcare company. His work at Merck has allowed him to focus on innovative solutions for viral infections, contributing to advancements in medical treatments. His patent reflects his commitment to addressing significant health issues through scientific research and development.
Collaborations
Koeplinger has collaborated with notable colleagues such as Gabor Butora and Malcolm MacCoss. These collaborations have likely enhanced the research and development process, leading to more effective solutions in the field of viral infections.
Conclusion
Kenneth Alan Koeplinger's contributions to the treatment of RNA-dependent RNA viral infections through his innovative patent demonstrate his dedication to improving healthcare. His work continues to impact the pharmaceutical industry positively.